"Impact of a Nursing Intervention in the Management of Oncological Patients With Lung Cancer Under Treatment With Immunotherapy"
Introduction. Lung cancer is very common worldwide with 2.09 million cases in 2018. Immunotherapy has become a mainstay in cancer treatment. There is insuficient knowledge about the impact of altered needs, as well as the interventions developed by the nurse that are aimed at cancer patients in immunotherapy treatment.
Objectives. Describe the needs of non-microcytic lung cancer patients in immunotherapy. And, evaluate the effectiveness of a nurse intervention program aimed at these patients in decreasing comorbidities, increasing satisfaction, early detection of symptoms and management of toxicities, quality of life and monitoring of anthropometric indicators.
Methodology. Phase 1: descriptive, cross-cutting and prospective study. Phase 2: quasi-experimental pre-post study. The sample is patients of the Hospital de la Santa Creu i Sant Pau, with non-microcytic lung cancer in treatment with Checkpoints inhibitor antibodies. The dependent variables: sociodemographic variables, clinical variables, satisfaction, quality of life, nutritional status, psychological impact, toxicities, number of unscheduled visits and health costs. Independent variable: nurse intervention program.
Implications for practice: Knowing the needs of patients in immunotherapy treatment will allow the development of a nurse care program to meet these needs and evaluate the program.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08025
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spain, 08041
- Jorgina Serra López
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient of legal age (> or equal to 18 years), either male or female.
- Patient diagnosed with lung cancer regardless of subtype and / or stage. Except for small cell lung cancer, since this subtype of lung cancer is very different from the others and requires its own study.
- Patient receiving immunotherapy regardless of the treatment line.
- Patient who receives immunotherapy regardless of whether it is monotherapy or combination of chemotherapy.
- Patient who is able to consent to participate in the study.
- Patient who can read, understand and can communicate verbally.
Exclusion Criteria:
- Patient diagnosed with lung cancer synchronously with another neoplasm.
- Patients with speech disorders.
- Patients who do not understand or speak Spanish, Catalan or English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Intervention arm
quasi-experimental pre-post study
|
Implementation of a specific care program for patients receiving immunotherapy for lung cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of altered needs of patients with lung cancer undergoing treatment with immunotherapy
Time Frame: one day
|
Detect the altered needs of patients with lung cancer in immunotherapy treatment.
In order to outline the best intervention program that suits their needs.
Through assessment through scales and questionnaires.
|
one day
|
|
Changes on anxiety in lung cancer patients with immunotherapy treatment measured by Hospital Anxiety and Depression Scale (HADS)
Time Frame: 6 months
|
Assess the patient's level of anxiety from diagnosis and prior to initiating treatment up to 6 months after initiating treatment.
Using the Hospital Anxiety and Depression Scale (HADS)
|
6 months
|
|
Changes on quality of life in lung cancer patients with immunotherapy treatment measured by EORTC quality of life scale
Time Frame: 6 months
|
Assess the quality of life of lung cancer patients from before starting immunotherapy up to 6 months after starting it.
Through the EORTC QLQ-LC 30.
|
6 months
|
|
Number of immunomediated toxicities requiring hospital admission
Time Frame: 6 months
|
Record the number and type of toxicities that require hospital admission for its management.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of nutritional alterations in patients with lung cancer, who start immunotherapy treatment
Time Frame: 6 months
|
Through the Nutriscore scale and to records of specific values of the blood analysis of the nutritional status of patients with lung cancer before starting immunotherapy and 6 months after starting it.
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIBSP-IIE-2020-77
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.